The antibodies target a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

A prophylactic antibody-based immune therapy protects monkeys against severe disease caused by H5N1 avian flu, University of ...

The antibody targets a stable part of the bird flu virus, ensuring that the immune protection can resist new variants and offer long-term protection against the globally spreading airborne infection.

HEALTH OFFICIALS IN NEW HAMPSHIRE SAY FIVE PEOPLE HAVE DIED FROM THE FLU SO FAR THIS SEASON, AS WE’VE BEEN REPORTING. AS YOU PROBABLY NOTICED IN YOUR DAILY LIFE, THE STATE IS SEEING HIGH NUMBERS OF ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Compared with placebo, fostamatinib did not increase the number of oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.